Veeva Systems, Inc. VEEV and Bioforum recently announced that they have collaborated with RedHill Biopharma Ltd ("RedHill") on a global Phase 2/3 clinical study evaluating opaganib, which is a first-in-class, orally-administered, sphingosine kinase-2 (SK2) selective inhibitor. The study will be conducted in patients who have been hospitalized with severe COVID-19 pneumonia requiring treatment with supplemental oxygen.
This should boost Veeva’s portfolio of cloud-based offerings for the life sciences industry.
More on the Collaboration
The opaganib Phase 2/3 study is set to enroll up to 270 patients in up to 40 clinical sites globally and gather broad and rigorous data in a short span of time. To facilitate the study, RedHill has adopted Veeva Vault CDMS, which is a modern cloud platform equipped in electronic data capture (EDC), coding, data cleaning and reporting.
Vault CDMS provides RedHill with a flexible EDC that simplifies and streamlines processes for establishing and implementing clinical studies. Bioforum, a global data-focused contract research organization (CRO) and a certified Veeva partner, has been picked by RedHill, a long-time client, to deploy and configure Vault CDMS for this COVID-19 study.
The goal of this collaboration is to cater to the urgent unmet medical need for safe, efficient and life-saving treatments for patients afflicted with severe cases of COVID-19. The partnership with Bioforum and Veeva will enable RedHill to compile clinical data as early as the fourth quarter of 2020 in order to support potential applications for emergency use authorizations of opaganib.
Vault CDMS enables trial sponsors and their CRO partners to manage studies jointly from development through execution. Veeva Vault EDC, part of Vault CDMS, offers an intuitive interface for capturing trial data and is developed for flexibility.
Per a report by MarketsandMarkets, the global cloud computing market size is expected to rise from $371.4 billion in 2020 to $832.1 billion by 2025, at a CAGR of 17.5%.
This month,Veeva Systems announced that Switzerland-based Idorsia Pharmaceuticals has chosen Veeva Commercial Cloud to enable its digital field force in the United States, Japan and countries across Europe. Veeva Commercial Cloud will help Idorsia build the foundation for digital excellence through multichannel engagement, data, content and analytics.
Apart from this, Veeva Systems announced recently that AstraZeneca has selected Veeva Vault QMS and Veeva Vault QualityDocs to combine quality management and content on a single cloud platform. This development is expected to enhance Veeva Systems’ commitment toward strengthening its cloud-based software.
Shares of this Zacks Rank #3 (Hold) company have gained 20.3% compared with the industry’s growth of 18.9% in the past three months.
A few better-ranked stocks from the broader medical space include NextGen Healthcare NXGN, Surmodics SRDX and Thermo Fisher Scientic. TMO.
NextGen’s long-term earnings growth rate is estimated at 8%. The company presently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Surmodics’ long-term earnings growth rate is estimated at 10%. The company presently carries a Zacks Rank #2.
Thermo Fisher’s long-term earnings growth rate is estimated at 15.5%. It currently carries a Zacks Rank #2.
Just Released: Zacks’ 7 Best Stocks for Today
Experts extracted 7 stocks from the list of 220 Zacks Rank #1 Strong Buys that has beaten the market more than 2X over with a stunning average gain of +24.3% per year.
These 7 were selected because of their superior potential for immediate breakout.
See these time-sensitive tickers now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Surmodics, Inc. (SRDX) : Free Stock Analysis Report
Thermo Fisher Scientific Inc. (TMO) : Free Stock Analysis Report
Veeva Systems Inc. (VEEV) : Free Stock Analysis Report
NEXTGEN HEALTHCARE, INC (NXGN) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research